Loading organizations...
AnHeart Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies for solid tumors, operating primarily out of Hangzhou, China, and New York, New York. The organization focuses on targeted treatments for complex cancers, advancing lead drug candidates like taletrectinib for ROS1-positive non-small cell lung cancer and safusidenib for mutant IDH1 gliomas. Prior to its exit, the enterprise raised over $100 million in total venture funding, which included an oversubscribed $61 million Series B round backed by institutional investors such as Octagon Capital Advisors and Decheng Capital. In April 2024, the business was acquired by Nuvation Bio in an all-stock transaction, transitioning into a wholly owned subsidiary to further its pivotal Phase 2 clinical trials and regulatory approvals. AnHeart Therapeutics was founded in 2018 by Junyuan (Jerry) Wang, Lihua Zheng, and Bing Yan.
AnHeart Therapeutics has raised $81.0M across 2 funding rounds.
AnHeart Therapeutics has raised $81.0M in total across 2 funding rounds.
AnHeart Therapeutics has raised $81.0M in total across 2 funding rounds.
AnHeart Therapeutics's investors include Ting Jia (TJ), Cenova Capital, Innovent Biologics, Laurion Capital Management, Sage Partners.
AnHeart Therapeutics has raised $81.0M across 2 funding rounds. Most recently, it raised $61.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 14, 2021 | $61M Series B | Ting JIA (tj) | Cenova Capital, Innovent Biologics, Laurion Capital Management, Sage Partners | Announced |
| Aug 10, 2020 | $20M Series A | — | — | Announced |
